🎉 M&A multiples are live!
Check it out!

Cyclopharm Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cyclopharm and similar public comparables like Philips, InfuSystem, and Myomo.

Cyclopharm Overview

About Cyclopharm

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.


Founded

2005

HQ

Australia
Employees

87

Financials

LTM Revenue $20.0M

LTM EBITDA -$5.8M

EV

$94.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Cyclopharm Financials

Cyclopharm has a last 12-month revenue of $20.0M and a last 12-month EBITDA of -$5.8M.

In the most recent fiscal year, Cyclopharm achieved revenue of $16.7M and an EBITDA of -$2.0M.

Cyclopharm expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Cyclopharm valuation multiples based on analyst estimates

Cyclopharm P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $14.7M $16.7M XXX XXX XXX
Gross Profit $8.0M $10.0M XXX XXX XXX
Gross Margin 55% 60% XXX XXX XXX
EBITDA -$3.2M -$2.0M XXX XXX XXX
EBITDA Margin -22% -12% XXX XXX XXX
Net Profit -$3.2M -$4.2M XXX XXX XXX
Net Margin -22% -25% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Cyclopharm Stock Performance

As of March 14, 2025, Cyclopharm's stock price is AUD 1 (or $1).

Cyclopharm has current market cap of AUD 162M (or $103M), and EV of AUD 150M (or $94.8M).

See Cyclopharm trading valuation data

Cyclopharm Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$94.8M $103M XXX XXX XXX XXX $-0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Cyclopharm Valuation Multiples

As of March 14, 2025, Cyclopharm has market cap of $103M and EV of $94.8M.

Cyclopharm's trades at 4.7x LTM EV/Revenue multiple, and -16.3x LTM EBITDA.

Analysts estimate Cyclopharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Cyclopharm and 10K+ public comps

Cyclopharm Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $94.8M XXX XXX XXX
EV/Revenue 5.7x XXX XXX XXX
EV/EBITDA -46.5x XXX XXX XXX
P/E -34.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -19.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Cyclopharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Cyclopharm Valuation Multiples

Cyclopharm's NTM/LTM revenue growth is 65%

Cyclopharm's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Cyclopharm's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Cyclopharm's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Cyclopharm and other 10K+ public comps

Cyclopharm Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 13% XXX XXX XXX XXX
EBITDA Margin -12% XXX XXX XXX XXX
EBITDA Growth -36% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 53% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 8% XXX XXX XXX XXX
G&A Expenses to Revenue 53% XXX XXX XXX XXX
R&D Expenses to Revenue 14% XXX XXX XXX XXX
Opex to Revenue 99% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Cyclopharm Public Comps

See public comps and valuation multiples for Medical Devices and Medical Imaging & Diagnostics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
SmartVest XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
Myomo XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Cyclopharm M&A and Investment Activity

Cyclopharm acquired  XXX companies to date.

Last acquisition by Cyclopharm was  XXXXXXXX, XXXXX XXXXX XXXXXX . Cyclopharm acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Cyclopharm

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Cyclopharm

When was Cyclopharm founded? Cyclopharm was founded in 2005.
Where is Cyclopharm headquartered? Cyclopharm is headquartered in Australia.
How many employees does Cyclopharm have? As of today, Cyclopharm has 87 employees.
Is Cyclopharm publicy listed? Yes, Cyclopharm is a public company listed on ASX.
What is the stock symbol of Cyclopharm? Cyclopharm trades under CYC ticker.
When did Cyclopharm go public? Cyclopharm went public in 2007.
Who are competitors of Cyclopharm? Similar companies to Cyclopharm include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem.
What is the current market cap of Cyclopharm? Cyclopharm's current market cap is $103M
What is the current revenue of Cyclopharm? Cyclopharm's last 12-month revenue is $20.0M.
What is the current EBITDA of Cyclopharm? Cyclopharm's last 12-month EBITDA is -$5.8M.
What is the current EV/Revenue multiple of Cyclopharm? Current revenue multiple of Cyclopharm is 4.7x.
What is the current EV/EBITDA multiple of Cyclopharm? Current EBITDA multiple of Cyclopharm is -16.3x.
What is the current revenue growth of Cyclopharm? Cyclopharm revenue growth between 2023 and 2024 was 13%.
Is Cyclopharm profitable? Yes, Cyclopharm is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.